Heidelberg University

Cannabis Science Inc., Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking

Retrieved on: 
Tuesday, August 10, 2021

Amsterdam, Netherlands, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Science Inc., Formerly known as (CBIS) per its previous trading history on the OTC Markets Exchange, is very Pleased to announce it has just successfully launched its $CSI Cannabis Science Coin, Utility for CSi-EDP project asset valuation, revenue tracking, and dividend disbursements.  As well, the CSi-EDP will use the $CSI Cannabis Science Coin for several of its transaction-based products and services. Each Cannabis Science CSi-EDP product and or service assigned will become a part of the $CSI Cannabis Science Coin investment banking and economic development eco system, thus multiplying the $CSI Cannabis Science Coin value and International reach!

Key Points: 
  • This $CSI Cannabis Science Coin Launch is important for Cannabis Science and we the people; this gives everyone access to the CSi-EDP, you already know the Cannabis Science list.
  • We will bank/assign one Cannabis Science CSI-EDP project at a time through our $CSI Cannabis Science Coin just like Currency, just like an Investment Bank!
  • We will announce each project one by one as we assign it to the $CSI Cannabis Science Coin in turn the growing in value for each CSI-EDP project added, based on crypto recorded valuations of each project and current $CSI Cannabis Science Coin values at any time.
  • That potential $CSI Cannabis Science Coin list is growing, and we need to go one by one for proper valuations of all our potential $CSI Cannabis Science Coin list of assets!!

SOFIE And University Clinic Heidelberg Sign License Agreement For Theranostics That Target Cancer Associated Fibroblasts

Retrieved on: 
Friday, June 21, 2019

LOS ANGELES and HEIDELBERG, Germany, June 21, 2019 /PRNewswire/ --SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics ("theranostics") that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells.

Key Points: 
  • LOS ANGELES and HEIDELBERG, Germany, June 21, 2019 /PRNewswire/ --SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics ("theranostics") that are designed to identify and break down cancer associated fibroblasts in tumor stroma and irradiate nearby cancer cells.
  • More than 200 patientswere imaged at the University Clinic Heidelberg, as well as five other academic centers in Germany investigating patients with a wide range of cancers.
  • "Cancer associated fibroblasts have been described as immunosuppressive and as conferring resistance to chemotherapy, which makes them attractive targets for combination therapies.
  • Jointly with the German Cancer Research Center (DKFZ) and German Cancer Aid, Heidelberg University Hospital has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.